Piperacillin/Tazobactam: A New Beta-Lactam/Beta-Lactamase Inhibitor Combination

No abstract is available for this paper.

• Publication year

  1995

• Venue

  The Annals of Pharmacotherapy

• Publication date

  1995-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/106002809502900510PMID 7655135
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Piperacillin/tazobactam/amikacin versus piperacillin/amikacin/teicoplanin in the empirical treatment of neutropenic patients

  2005cited by this paper
• Piperacillin and Tazobactam Versus Clindamycin and Gentamicin in the Treatment of Hospitalized Women With Pelvic Infection

  1994cited by this paper
• Piperacillin/tazobactam compared with ticarcillin/clavulanate in community-acquired bacterial lower respiratory tract infection.

  1994cited by this paper
• Prospective randomized study of piperacillin/tazobactam therapy of surgically treated intra-abdominal infection. The Piperacillin/Tazobactam Intra-Abdominal Infection Study Group.

  1993cited by this paper
• Susceptibility of anaerobes in phase 3 clinical studies of piperacillin/tazobactam.

  1993cited by this paper
• The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam.

  1993cited by this paper
• Efficacy, safety and tolerance of parenteral piperacillin/tazobactam in the treatment of patients with lower respiratory tract infections.

  1993cited by this paper
• Therapy of soft tissue infections with piperacillin/tazobactam.

  1993cited by this paper
• Piperacillin/tazobactam versus imipenem/cilastatin in the treatment of intra-abdominal infections.

  1993cited by this paper
• Treatment of hospitalized patients with complicated skin and skin structure infections: double-blind, randomized, multicenter study of piperacillin-tazobactam versus ticarcillin-clavulanate. The Piperacillin/Tazobactam Skin and Skin Structure Study Group

  1993cited by this paper
• Comparison of fixed concentration and fixed ratio options for testing susceptibility of gram-negative bacilli to piperacillin and piperacillin/tazobactam

  1992cited by this paper
• Piperacillin-tazobactam versus imipenem-cilastatin for treatment of intra-abdominal infections

  1992cited by this paper
• Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery

  1992cited by this paper
• Single‐dose pharmacokinetics of piperacillin and tazobactam in patients with renal disease

  1992cited by this paper
• Ceftazidime monotherapy for empiric treatment of febrile neutropenic patients: a meta-analysis.

  1991cited by this paper
• Effect of beta-lactamase inhibitors on the activities of various beta-lactam agents against anaerobic bacteria

  1991cited by this paper
• Pharmacokinetics and tissue penetration of tazobactam administered alone and with piperacillin

  1991cited by this paper
• In vitro effect of YTR (tazobactam) on plasmid and chromosomally mediated beta-lactamases.

  1990cited by this paper
• Inhibition of beta-lactamases by tazobactam and in-vitro antibacterial activity of tazobactam combined with piperacillin.

  1990cited by this paper
• Beta-lactamase production in members of the family Enterobacteriaceae and resistance to beta-lactam-enzyme inhibitor combinations

  1990cited by this paper
• The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria.

  1990cited by this paper
• Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria

  1990cited by this paper
• Studies to optimize the in vitro testing of piperacillin combined with tazobactam (YTR 830).

  1989cited by this paper
• Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.

  1989cited by this paper
• Comparative in vitro activity of piperacillin combined with the beta-lactamase inhibitor tazobactam (YTR 830).

  1989cited by this paper
• Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam

  1989cited by this paper
• Comparative in vitro activities of piperacillin-tazobactam and ticarcillin-clavulanate

  1989cited by this paper
• Comparative evaluation of a new beta-lactamase inhibitor, YTR 830, combined with different beta-lactam antibiotics against bacteria harboring known beta-lactamases

  1986cited by this paper
• Effects of sodium piperacillin on platelet function in normal volunteers

  1981cited by this paper

• Biochemical Characterization and Antibiotic Susceptibility Analysis of Escherichia coli and Salmonella typhi Isolated from Clinical Sample

  2025cites this paper
• Piperacillin Pharmacokinetics in a Pediatric Patient With Primary Hyperoxaluria Receiving High-Dose Continuous Dialysis Post Liver-Kidney Transplant.

  2025cites this paper
• Exploring local adjuvant antibiotics as viable alternative to systemic antibiotics in non-surgical periodontal therapy: Clinical, immunological and microbiological insights

  2025cites this paper
• Piperacillin/Tazobactam is associated with a higher risk of acute kidney injury compared to cefepime and meropenem

  2025cites this paper
• Strategies for Updating Piperacillin-Tazobactam Breakpoints

  2023cites this paper
• Piperacillin Pharmacokinetics and Pharmacodynamics in Paediatric Patients Who Received High Frequency Piperacillin/Tazobactam Dosing Intra-Operatively.

  2023cites this paper
• Piperacillin-tazobactam: prospects for use in real-world practice

  2023cites this paper
• Design and development of an efficient convergent synthetic strategy for novel β-lactam enhancer zidebactam (WCK 5107)

  2023cites this paper
• Piperacillin-tazobactam induced immune hemolytic anemia led to increased renal impairment and eventual death from multiple organ failure in a patient with hypertensive nephropathy: case report and literature review

  2023cites this paper
• Comparison of Cefepime with Piperacillin/Tazobactam Treatment in Patients with Hospital-Acquired Pneumonia

  2023cites this paper
• Click Synthesis, Characterization, Mesomorphic Properties, and Antimicrobial Evaluation of Some Novel Imidazo[1,2-a]pyrazine Derivatives Containing a 1,2,3-Triazole Ring

  2023cites this paper
• Docking covalent targets for drug discovery: stimulating the computer-aided drug design community of possible pitfalls and erroneous practices

  2022cites this paper
• Relationship between piperacillin concentrations, clinical factors and piperacillin/tazobactam-associated acute kidney injury.

  2022cites this paper
• A case of hypertensive nephropathy who died of piperacillin- tazobactam induced immune hemolytic anemia which aggravated renal dysfunction: complete follow-up of serology and disease course

  2022cites this paper
• Design, Synthesis and Molecular Docking Studies of Novel Indole–Isoxazole–Triazole Conjugates as Potent Antibacterial Agents

  2021cites this paper
• Hematologic adverse effects induced by piperacillin–tazobactam: a systematic review of case reports

  2020cites this paper
• Ultrasound assisted rapid synthesis, biological evaluation, and molecular docking study of new 1,2,3-triazolyl pyrano[2,3-c]pyrazoles as antifungal and antioxidant agent

  2019cites this paper
• Multicentre evaluation of the new ETEST gradient diffusion method 1 for piperacillin-tazobactam susceptibility testing of Enterobacterales , 2 Pseudomonas aeruginosa and Acinetobacter baumannii complex 3

  2019cites this paper
• A novel framework to compare the effectiveness of β-lactamase inhibitors against extended-spectrum β-lactamase-producing Enterobacteriaceae.

  2019cites this paper
• Multicenter Evaluation of the New Etest Gradient Diffusion Method for Piperacillin-Tazobactam Susceptibility Testing of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii Complex

  2019cites this paper
• Population Pharmacokinetics and Safety of Piperacillin-Tazobactam Extended Infusions in Infants and Children

  2019cites this paper
• Current and emerging pharmacotherapy for the treatment of bacterial peritonitis

  2018cites this paper
• Individualizing piperacillin/tazobactam dosing in adult patients with cystic fibrosis: can tobramycin measurements help?

  2018cites this paper
• Optimal Piperacillin-Tazobactam Dosing Strategies against Extended-Spectrum-β-Lactamase-Producing Enterobacteriaceae

  2018cites this paper
• Design, Synthesis and Molecular Docking Studies of Novel Triazole‐Chromene Conjugates as Antitubercular, Antioxidant and Antifungal Agents

  2018cites this paper
• Single-Dose Pharmacokinetics of Piperacillin/Tazobactam in Hispaniolan Amazon Parrots (Amazona ventralis)

  2017cites this paper
• Effective in Vitro Synergy of Piperacillin/Tazobactam Plus either Netilmicin or Aztreonam against Metallo-β-lactamase-producing Pseudomonas Aeruginosa

  2016cites this paper
• Carbapenem therapy is associated with improved survival compared with piperacillin-tazobactam for patients with extended-spectrum β-lactamase bacteremia.

  2015cites this paper
• Pharmacokinetics and Pharmacodynamics of Antibacterial and Antifungal Agents in Adult Patients With Thermal Injury: A Review of Current Literature

  2015cites this paper
• Complicated Intra-Abdominal Infections: The Old Antimicrobials and the New Players

  2015cites this paper
• MARKET RESEARCH ON USAGE OF ANTIBIOTICS IN SERIOUS INFECTIONS Original Article

  2014cites this paper
• Cost Efficacy of Tazobactam/Piperacillin versus Imipenem/Cilastatin in the Treatment of Intra-Abdominal Infection

  2012cites this paper
• CHAPTER 37 – Clinical Pharmacology of Anti-Infective Drugs

  2011cites this paper
• Therapeutic options for diabetic foot infections: a review with an emphasis on tissue penetration characteristics.

  2010cites this paper
• Experience with the use of piperacillin–tazobactam in pediatric non‐renal solid organ transplantation

  2007cites this paper
• Comparison of the Pharmacokinetics of Piperacillin and Sulbactam during Intermittent and Continuous Intravenous Infusion

  2007cites this paper
• Piperacillin/Tazobactam–Induced Paresthesiae

  2006cites this paper
• Piperacillin-tazobactam-induced drug hypersensitivity syndrome.

  2006cites this paper
• Effects of Freezing, Long-Term Storage, and Microwave Thawing on the Stability of Piperacillin Plus Tazobactam in 5% Dextrose for Infusion

  2004cites this paper
• Incidence of neutropenia during treatment of bone-related infections with piperacillin-tazobactam.

  2003cites this paper
• Clinafloxacin versus piperacillin/tazobactam in the treatment of severe skin and soft-tissue infections in adults at a Veterans Affairs medical center.

  2002cites this paper
• Piperacillin/tazobactam versus cefotaxime plus metronidazole for the treatment of severe intra-abdominal infection in hospitalized pediatric patients

  2001cites this paper
• The Role of β-Lactam Antimicrobials as Single Agents in Treatment of Intra-Abdominal Infection

  2000cites this paper
• The role of beta-lactam antimicrobials as single agents in treatment of intra-abdominal infection.

  2000cites this paper
• Piperacillin/Tazobactam

  1999cites this paper
• Piperacillin and Tazobactam Exhibit Linear Pharmacokinetics after Multiple Standard Clinical Doses

  1999cites this paper
• Piperacillin/tazobactam: an updated review of its use in the treatment of bacterial infections.

  1999cites this paper
• β-Lactam antibiotics, β-lactamases and bacterial resistance

  1998cites this paper
• Characterization of a PSE-4 Mutant with Different Properties in Relation to Penicillanic Acid Sulfones: Importance of Residues 216 to 218 in Class A β-Lactamases

  1998cites this paper
• A review of the pharmacokinetic and pharmacodynamic characteristics of beta-lactam/beta-lactamase inhibitor combination antibiotics in premature infants.

  1998cites this paper
• Pharmacokinetics and pharmacodynamics of two multiple-dose piperacillin-tazobactam regimens

  1997cites this paper
• Piperacillin/Tazobactam (ZOSYN)

  1996cites this paper
• A Practical Look at the Clinical Usefulness of the Beta-Lactam/Beta-Lactamase Inhibitor Combinations

  1996cites this paper
• Comment: piperacillin/tazobactam: a new beta-lactam/beta-lactamase inhibitor combination

  1995cites this paper
• Becker Digital

  year unknowncites this paper
• Carbapenem Therapy Is Associated with Improved Survival Compared with Piperacillin- Tazobactam for Patients with Extended- Spectrum Β-lactamase Bacteremia ; for the Antibacterial Resistance Leadership Group

  year unknowncites this paper